Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This retrospective pilot study found that oral tofacitinib was more effective in treating alopecia areata than alopecia universalis, but relapses were common after treatment cessation.

This review discusses the possible link between cosmeceuticals and frontal fibrosing alopecia but reports no conclusive findings; the authors stress further research on environmental triggers is needed.

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

This study examined 56 Thai patients with frontal fibrosing alopecia, finding frontotemporal hairline recession and eyebrow loss were common, and reported better disease stabilization with combination treatments of topical corticosteroids with hydroxychloroquine or finasteride.

This meta-analysis found a significant positive association between frontal fibrosing alopecia and both sunscreen and moisturizer use, with the moisturizer association significant only in males.

In this ex vivo and mouse model study, Tofacitinib-loaded nanoparticles demonstrated enhanced delivery of the drug into hair follicles and reduced inflammatory effects compared to conventional forms, indicating potential for safer, topical use in treating alopecia areata.

This study involved 69 hair experts using a Delphi process to achieve consensus on treating frontal fibrosing alopecia, finding strong agreement on disease monitoring but less on physical and systemic therapies, indicating the need for more research.

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

This case report documented successful full hair regrowth in an 8-year-old with alopecia universalis after oral tofacitinib treatment, but mild headaches led to discontinuation.

This study found that key amino acids lost from hair due to weathering can be successfully reintroduced through cosmetic treatments, improving hair strength and aesthetics.

This case report highlights that frontal fibrosing alopecia can occur in black patients and may resemble androgenetic alopecia, underscoring the importance of considering FFA when diagnosing frontotemporal alopecia in this population.

This letter discusses a previous study on tofacitinib for alopecia areata, questioning its statistical analysis and suggesting that steroids may have influenced results, but it reports no new clinical findings.

This systematic review discusses the treatment characteristics and outcomes for frontal fibrosing alopecia specifically in Black patients with skin of color, addressing a gap in clinical evidence due to underrepresentation in studies.

This review discusses the current understanding of frontal fibrosing alopecia's pathogenesis, highlighting genetic susceptibility, immune response involvement, and possible links to steroid hormones, but reports no new clinical results.

Early diagnosis and a multidisciplinary approach are crucial for managing Frontal Fibrosing Alopecia.

In this study, oral tofacitinib significantly reduced alopecia severity in pediatric patients with moderate-to-severe alopecia areata over 24 weeks, with 42.2% achieving complete or near-complete hair regrowth, although further research is needed on long-term safety and relapse rates.

This study found that oral tofacitinib at a 5mg twice daily dosage was effective in treating recalcitrant alopecia areata, showing significant improvement in hair regrowth and a 27% reduction in SALT scores over six months, with minimal side effects among the 19 patients monitored.

Pre-natal, internal, and external factors may contribute to the development of Autism Spectrum Disorder (ASD).

This article notes slow progression and spontaneous stabilization in untreated cases of a specific scarring alopecia and reports no new results; the authors call for randomized trials to confirm the treatment's benefit.

This research describes using advanced mass spectrometry imaging techniques to analyze gunshot residue and map molecular components in biological samples, such as tumors and mosquito ovarian follicles, at unprecedented spatial resolution and specificity.

This study identified a new FAK isoform, FAKΔe4, which is regulated by ECM stiffness and affects cell migration, invasion, and mechanosensing in human-derived data and engineered models.

This study found that tofacitinib effectively promoted hair regrowth in Asian patients with severe alopecia areata, with 74.3% showing a clinical response.

This retrospective study found that oral tofacitinib significantly reduced the severity of alopecia areata in children, achieving over a 50% reduction in hair loss severity, though relapse occurred during treatment tapering, and mild adverse effects were noted.

This study found that tofacitinib shows reasonable effectiveness for treating alopecia areata with mild adverse effects, although more large-scale randomized trials are needed to fully assess its safety and efficacy.

This study found that adipocytes in the interfacial white adipose tissue adjacent to fibrotic lesions in systemic sclerosis show unique phenotypes and contribute to the condition's pathogenesis.

This study found that eyelash loss, facial papules, and body hair involvement were linked to severe frontal fibrosing alopecia, and antiandrogens were the most effective treatment.

In this study, researchers observed that phospholipid-calcium carbonate hybrid nanoparticles effectively delivered Tofacitinib citrate topically, which significantly inhibited hair follicle apoptosis and promoted hair growth in a mouse model of chemotherapy-induced alopecia, compared to a traditional Tofacitinib solution.

This study found that tofacitinib was a safe and effective treatment for patients with moderate-to-severe alopecia areata, with a significant percentage achieving notable reductions in their Severity of Alopecia Tool scores after 18 months.

In this study, sensitization to ethylhexyl salicylate was found in 27.3% of patients with frontal fibrosing alopecia, suggesting it may be a potential contact allergen for this condition.